2026-04-17T12:13:32Zhttps://recercat.cat/oai/requestoai:recercat.cat:2445/2165572025-12-05T12:00:58Zcom_2072_1057col_2072_478916col_2072_478917
RECERCAT
author
Cabañero Navalon, Marta Dafne
author
Garcia Bustos, Victor
author
Balastegui Martin, Héctor
author
Bracke, Carmen
author
Mateu, Lourdes
author
Solanich, Xavier
author
Carrillo Linares, Juan Luis
author
Robles Marhuenda, Angel
author
Puchades, Francesc
author
Pelaez Ballesta, Ana
author
Lopez Osle, Nuria
author
Torralba Cabeza, Miguel Ángel
author
Bielsa Masdeu, Ana María
author
Gil Niño, Jorge
author
Tornador Gaya, Nuria
author
Castellanos, Guillem Pascual
author
Sánchez Martínez, Rosario
author
Barragán Casas, José Manuel
author
González García, Andrés
author
Patier De La Peña, José Luis
author
López Wolf, Daniel
author
Mora Rufete, Antonia
author
Canovas Mora, Alba
author
Moral Moral, Pedro
2024-11-18T12:29:08Z2024-11-18T12:29:08Z2024-10-162024-11-18T12:12:39Z
Background: Common Variable Immunodeficiency (CVID) represents a heterogenic group of primary immunodeficiencies (PID) characterized by impaired antibody production and susceptibility to infections. Non-infectious complications, such as autoimmune diseases, lymphoproliferative disorders, and malignancies, now significantly impact prognosis. Moreover, both hematologic and solid organ malignancies are more frequently observed in CVID patients compared to other PIDs. The risk factors for carcinogenesis in CVID remain largely unknown. Objective: This multicenter study aims to characterize the clinical profile of cancer in CVID patients in Spain and to identify independent risk factors associated with malignancy development, focusing on the role of immune dysregulation. Methods: A nationwide, cross-sectional study was conducted from November 2019 to May 2022, involving 17 hospitals treating PID patients in Spain. Data were collected systematically on demographics, infectious and non-infectious comorbidities, immunological parameters, and treatment. Statistical analysis, including multivariate logistic regression, was performed to identify risk factors associated to malignancy. Results: Of 250 CVID patients, 38 (15.26%) were diagnosed with cancer, predominantly non-Hodgkin lymphoma, gastric cancer, and lung adenocarcinoma. Cancer patients were significantly older (mean age 60.70 vs. 49.36 years, p<0.001) and had higher rates of immune dysregulation (81.58% vs. 59.7%, p=0.01). Immune dysregulation was an independent risk factor for cancer (OR 2.19, p=0.04), alongside previous immunosuppressant therapy (OR 2, p=0.031), higher IgM levels (OR 1.008 per SD, p=0.012), older age (OR 1.04, p<0.001), and lower CD4 cell counts at diagnosis (OR 0.997, p<0.001). Conclusions: This study highlights the increased cancer risk in CVID patients, with immune dysregulation, prior immunosuppressant use, elevated IgM levels, and lower CD4 cell counts as conjointly associated. These findings underscore the need for vigilant cancer screening and tailored management strategies in CVID patients to improve outcomes. Future research should focus on elucidating the molecular mechanisms linking immune dysregulation and malignancy in CVID.
cc-by (c) Cabañero Navalon, Marta Dafne et al., 2024 http://creativecommons.org/licenses/by/3.0/es/ info:eu-repo/semantics/openAccess
Síndromes de deficiència immunitària
Càncer
Immunological deficiency syndromes
Cancer
The impact of immune dysregulation on the risk of malignancy in common variable immunodeficiency: insights from a multicenter study
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion